Apollomics, Inc. (APLM)

Apollomics, Inc. (APLM) Healthcare & Pipeline Overview

Apollomics, Inc. is a biotechnology firm specializing in the discovery and development of oncology therapies, targeting unmet medical needs across California, China, and Australia. With a focus on innovative treatments like APL-101, APL-102, and APL-122, the company aims to improve outcomes for patients with various cancers.

What Is the Investment Thesis for APLM?

Apollomics, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on developing targeted oncology therapies addresses a significant unmet medical need. APL-101, APL-102, and APL-122 each target specific cancer types and pathways, offering potential for significant clinical impact. However, the company's small market capitalization of $21.36M and negative profit margin of -128.7% indicate substantial financial challenges. Successful clinical trials and regulatory approvals for its drug candidates are critical catalysts. The company's high beta of 1.76 suggests significant volatility relative to the market. Investors should carefully consider the risks associated with biotechnology investments, including clinical trial failures, regulatory hurdles, and the need for substantial capital to fund ongoing research and development.

Based on FMP financials and quantitative analysis

APLM Key Highlights

• Market Cap of $21.36M reflects the company's small size and early stage in the biotechnology sector.
• Negative Profit Margin of -128.7% indicates that the company is currently operating at a loss, common for biotechnology firms investing heavily in R&D.
• Free Cash Flow (FCF) of $-0.01 billion shows the company is burning cash, highlighting the need for additional funding.
• Beta of 1.76 suggests the stock is more volatile than the market, indicating higher risk and potential reward.
• No Dividend Yield reflects the company's focus on reinvesting earnings into research and development rather than returning capital to shareholders.

Who Are APLM's Competitors?

APLM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are APLM's Key Strengths?

• Innovative pipeline of oncology therapies.
• Targeted therapies addressing specific unmet needs.
• Experienced management team with expertise in drug development.
• Global presence with operations in California, China, and Australia.

What Are APLM's Weaknesses?

• Small market capitalization and limited financial resources.
• Negative profit margin and reliance on external funding.
• High dependence on the success of its clinical trials.
• Limited commercial infrastructure.

What Could Drive APLM Stock Higher?

• Clinical trial results for APL-101 in non-small cell lung cancer expected in Q4 2026.
• Initiation of Phase 2 clinical trials for APL-102 in liver cancer in Q3 2026.
• Regulatory submissions for APL-101 in China expected in 2027.
• Strategic partnership discussions with pharmaceutical companies for co-development of APL-122.

What Are the Key Risks for APLM?

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for APL-101, APL-102, or APL-122.
• Regulatory delays or rejections for its drug candidates.
• Competition from larger pharmaceutical companies with greater resources.
• Dependence on external funding to support its operations.
• Patent expirations and generic competition.

What Are the Growth Opportunities for APLM?

• Expansion of APL-101 (Vebreltinib) indications: APL-101, a c-Met inhibitor, shows promise in treating non-small cell lung cancer and other advanced tumors. Expanding its clinical trials to include additional cancer types could significantly increase its market potential. The global market for lung cancer therapeutics is projected to reach $44.5 billion by 2027. Successful clinical trials and regulatory approvals for new indications could drive substantial revenue growth for Apollomics.
• Advancement of APL-102 into late-stage clinical trials: APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, targets liver cancer, breast cancer, and esophageal cancer. Progressing APL-102 into late-stage clinical trials and securing regulatory approvals could unlock significant market opportunities. The global market for liver cancer therapeutics is expected to reach $2.5 billion by 2028.
• Development of APL-122 for brain cancers: APL-122, a tumor inhibitor candidate, is designed to treat cancers within the brain. Developing this therapy could address a critical unmet need in the treatment of brain cancers. The global market for brain cancer therapeutics is projected to reach $3.5 billion by 2027. Successful development and commercialization of APL-122 could provide a significant competitive advantage for Apollomics.
• Strategic partnerships and collaborations: Forming strategic partnerships with larger pharmaceutical companies or research institutions could provide Apollomics with access to additional funding, expertise, and resources. Collaborations could accelerate the development and commercialization of its drug candidates. The biotechnology industry is characterized by frequent collaborations and partnerships, which are essential for navigating the complex regulatory and commercial landscape.
• Expansion into new geographic markets: Expanding operations into new geographic markets, particularly in Asia, could provide Apollomics with access to a larger patient population and increased revenue opportunities. The Asia-Pacific region is experiencing rapid growth in healthcare spending and increasing demand for innovative cancer therapies. Establishing a presence in key markets like China and Japan could drive long-term growth for Apollomics.

What Opportunities Does APLM Have?

• Expansion of existing drug candidates into new indications.
• Strategic partnerships and collaborations with larger pharmaceutical companies.
• Expansion into new geographic markets.
• Advancements in cancer diagnostics and personalized medicine.

What Threats Does APLM Face?

• Clinical trial failures and regulatory setbacks.
• Competition from larger pharmaceutical companies with greater resources.
• Pricing pressures and evolving reimbursement policies.
• Patent expirations and generic competition.

What Are APLM's Competitive Advantages?

• Proprietary drug candidates with patent protection.
• Specialized expertise in oncology drug development.
• Targeted therapies that address specific genetic and molecular targets in cancer cells.
• Strategic partnerships with research institutions and pharmaceutical companies.

What Does APLM Do?

Apollomics, Inc., established in 2015 and headquartered in Foster City, California, is a biotechnology company dedicated to the discovery and development of innovative oncology therapies. Originally incorporated as CBT Pharmaceuticals, Inc., the company rebranded to Apollomics, Inc. in January 2019, signaling a renewed focus on addressing unmet medical needs in cancer treatment. The company operates in California, Hangzhou, Shanghai, China, and Australia, reflecting its global strategy to develop and commercialize its therapies. Apollomics' pipeline includes several promising drug candidates, such as APL-101 (Vebreltinib), a selective c-Met inhibitor targeting non-small cell lung cancer and other advanced tumors. APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, is being developed for liver cancer, breast cancer, and esophageal cancer. APL-122, a tumor inhibitor candidate, is designed to treat cancers within the brain. These therapies represent Apollomics' commitment to developing targeted treatments for a range of cancers. With a small team of 13 employees, Apollomics is focused on advancing its pipeline through clinical trials and regulatory approvals, aiming to bring innovative cancer treatments to patients worldwide. The company's strategy involves identifying and developing therapies that address specific genetic and molecular targets in cancer cells, with the goal of improving treatment outcomes and patient survival rates. Apollomics is positioned to capitalize on the growing demand for personalized cancer therapies and the increasing prevalence of cancer globally.

What Products and Services Does APLM Offer?

• Discovers and develops oncology therapies.
• Focuses on addressing unmet medical needs in cancer treatment.
• Develops APL-101 (Vebreltinib) for non-small cell lung cancer and other advanced tumors.
• Develops APL-102 for liver cancer, breast cancer, and esophageal cancer.
• Develops APL-122 for cancers within the brain.
• Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
• Seeks regulatory approvals from agencies like the FDA and EMA.

How Does APLM Make Money?

• Develops and patents novel oncology therapies.
• Conducts clinical trials to demonstrate safety and efficacy.
• Seeks regulatory approvals to commercialize its therapies.
• Generates revenue through the sale of its approved therapies or through licensing agreements with other pharmaceutical companies.

What Industry Does APLM Operate In?

Apollomics, Inc. operates within the competitive biotechnology industry, which is characterized by rapid innovation, high regulatory hurdles, and significant financial risks. The global oncology market is projected to reach $378.4 billion by 2030, driven by an aging population and increasing cancer incidence rates. Apollomics competes with larger pharmaceutical companies and specialized biotechnology firms in developing novel cancer therapies. The company's success depends on its ability to secure regulatory approvals, demonstrate clinical efficacy, and establish strategic partnerships. The industry is also subject to intense pricing pressures and evolving reimbursement policies.

Who Are APLM's Key Customers?

• Patients with cancer who are in need of new treatment options.
• Oncologists and other healthcare professionals who prescribe cancer therapies.
• Hospitals and cancer centers that provide cancer treatment services.
• Pharmaceutical companies that may license or acquire Apollomics' therapies.

FY2026 estForward Outlook

Wall Street analysts project Apollomics, Inc. revenue of about $13.3M for fiscal 2026, with EPS near $-122.00.

F-Score 3/9Financial Health

Apollomics, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

ROE 288%Key Financial Metrics

Return on equity for Apollomics, Inc. stands at 288.4%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -81.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.96 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -183.6%, the inverse of the P/E and a quick read on earnings relative to price.

Apollomics, Inc. (APLM) Valuation Context

Valued at $21.36M, APLM is classified as a micro-cap stock. Relative to its peer group, APLM's quantitative score of 20/100 is below the peer average of 76/100.

APLM Revenue & Earnings Trend

In Q2 2025, APLM generated $8.5M in top-line revenue, marking a sequential increase of 380.8%. The company recorded a net loss of $12.5M, with diluted EPS of $-11.37.

Company Profile

Apollomics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Foster City, US. The company is led by CEO Hung-Wen Chen. APLM has traded publicly since 2021.

APLM Financials

APLM Latest News

APLM Analyst Consensus

APLM MoonshotScore

APLM Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources